miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Background. Sunitinib is a tyrosine kinase inhibitor used in the treatment of metastatic renal cell carcinoma. The main difficulty related to the treatment is the development of drug resistance followed by rapid progression of the disease. We analyzed tumor tissue of sunitinib treated patients in or...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Biomed Res Int
Hauptverfasser: Merhautova, Jana, Hezova, Renata, Poprach, Alexandr, Kovarikova, Alena, Radova, Lenka, Svoboda, Marek, Vyzula, Rostislav, Demlova, Regina, Slaby, Ondrej
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hindawi Publishing Corporation 2015
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433647/
https://ncbi.nlm.nih.gov/pubmed/26064968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/941980
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge